Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 20

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 20
---
 and backgrounds on the Board:

| • | Biotechnology & Related Industry Experience: experience within the biotechnology, pharmaceuticals, medical technologies or healthcare industries, particularly, experience with biologics and immunology therapeutic areas (e.g., dermatology or rheumatology) or experience in clinical development, operations or research and development. |

| • | Corporate Governance: experience, whether currently or in the past, serving on other public company boards of directors. |

| • | Diverse Perspectives: contributes to a diversity of occupations, perspectives and backgrounds on the Board, including with respect to skills, experiences, gender, race/ethnicity and sexual orientation. |

| • | Finance & Accounting: experience or expertise in finance, accounting, investment analysis, financial reporting processes and capital markets. |

| • | Sales & Marketing: experience overseeing or driving product sales, marketing and commercialization, particularly in the biotechnology and pharmaceuticals industries and in the context of payor or reimbursed and regulated markets. |

| • | Science & Research: scientific knowledge related to biotechnology and related industry experience, and experience in related research and clinical development. |

| • | Senior Leadership: experience serving in a leadership role of an organization, including driving strategy execution, organizational growth and managing human capital. |

The Nominating Committee generally believes it is important for all Board members to possess the highest personal and professional ethics, integrity and values, an inquisitive and objective perspective, a sense for priorities and balance, the ability and willingness to devote sufficient time and attention to Board matters, and a willingness to represent the long-term interests of all our shareholders. In addition to the factors discussed above, the Board and the Nominating Committee actively seek to achieve a diversity of occupations, perspectives and backgrounds on the Board. As part of the search process for new directors, the Nominating Committee seeks to include qualified candidates with diverse backgrounds in the pool from which the Committee selects the nominees with the skills, experience and qualifications that it believes best support the Company in the context of the Board as a whole. The Nominating Committee assesses its effectiveness in balancing these considerations in connection with its annual evaluation of the composition of the Board. For example, our current Board of six directors includes one director (16%) who self-identifies as female and one director (16%) who self-identifies as racially/ethnically diverse. Shareholder Recommendations for Directors It is the Nominating Committee’s policy to consider written recommendations from shareholders for director candidates. The committee considers candidates